References

1. Savinova I, Fournier A, Grieve S, Brunt KR. Plain language summary of a fingerprinting technique to monitor blood cancer. Nanomedicine (Lond.) 17(23), 1751–1756 (2023).
Google Scholar
2. Future Science Group. Plain Language Summaries. www.plainlanguagesummaries.com
Google Scholar
3. Wei L, Chen J, Ding J. Sequentially stimuli-responsive anticancer nanomedicines. Nanomedicine (Lond.) 16(4), 261–264 (2021).
CASGoogle Scholar
4. Jiang Y, Huo Z, Qi X, Zuo T, Wu Z. Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes. Nanomedicine (Lond.) 17(5), 303–324 (2022).
CASGoogle Scholar
5. Dimensions. https://app.dimensions.ai/discover/publication
Google Scholar
6. Rashidzadeh H, Danafar H, Rahimi H et al. Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus): diagnosis, treatment, therapy and future perspectives. Nanomedicine (Lond.) 16(6), 497–516 (2021).
CASGoogle Scholar
7. Vartak R, Patil SM, Saraswat A, Patki M, Kunda NK, Patel K. Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro. Nanomedicine (Lond.) 16(14), 1187–1202 (2021).
CASGoogle Scholar
8. Guglielmelli A, Rosa P, Contardi M et al. Biomimetic keratin gold nanoparticle-mediated in vitro photothermal therapy on glioblastoma multiforme. Nanomedicine (Lond.) 16(2), 121–138 (2021).
CASGoogle Scholar
9. Gatti AM, Ristic M, Stanzani S, Lavezzi AM. Novel chemical-physical autopsy investigation in sudden infant death and sudden intrauterine unexplained death syndromes. Nanomedicine (Lond.) 17(5), 275–288 (2022).
CASGoogle Scholar
10. Nelson BC, Borgos SE. High-throughput synthesis and characterization of next-generation lipid nanoparticles for enhanced in vivo performance. Nanomedicine (Lond.) 17(9), 573–576 (2022).
CASGoogle Scholar
11. Garcia CR, Rad AT, Saeedinejad F et al. Effect of drug-to-lipid ratio on nanodisc-based tenofovir drug delivery to the brain for HIV-1 infection. Nanomedicine (Lond.) 17(13), 959–978 (2022).
CASGoogle Scholar
12. Kabedev A, Lobaskin V. Endothelial glycocalyx permeability for nanoscale solutes. Nanomedicine (Lond.) 17(13), 979–996 (2022).
CASGoogle Scholar
13. Virmani T, Kumar G, Virmani R, Sharma A, Pathak K. Nanocarrier-based approaches to combat chronic obstructive pulmonary disease. Nanomedicine (Lond.) 17(24), 1833–1854 (2022).
CASGoogle Scholar
14. Dua K, Lobenberg R, Chellappan DK. Special focus issue on targeted drug delivery for inflammatory lung diseases. Nanomedicine (Lond.) 17(12), 813–815 (2022).
CASGoogle Scholar
15. Van Bavel N, Lai P, Loebenberg R, Prenner EJ. Vaping additives negatively impact the stability and lateral film organization of lung surfactant model systems. Nanomedicine (Lond.) 17(12), 827–843 (2022).
CASGoogle Scholar
16. LinkedIn. Nanomedicine. https://www.linkedin.com/groups/8774230/
Google Scholar

Vol. 18, No. 1

Metrics

Downloaded 522 times

History

Received 15 February 2023

Accepted 15 February 2023

Published online 30 March 2023

Published in print January 2023

Information

Keywords

Financial & competing interests disclosure

D Kytka-Sharpe is an employee of Future Science Group Ltd, publisher of Nanomedicine. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Welcome to volume 18 of Nanomedicine

References